Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBV-specific T-cell lines (Delisle)
- Development stage
- Unknown
- Lead developer
- Hôpital Maisonneuve-Rosemont
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
EBV-specific T-cell lines (EBV-CTLs) are an investigational adoptive cellular immunotherapy developed by Dr. Jean-Sebastien Delisle at Hôpital Maisonneuve-Rosemont. This therapy involves the ex vivo expansion and 'education' of T lymphocytes to recognize and eliminate cells infected with the Epstein-Barr virus (EBV). The T-cell lines are generated using peripheral blood mononuclear cells from either the patient (autologous) or a matched/partially matched related donor (allogeneic), which are then stimulated with EBV-specific peptides. The therapy is primarily intended for patients with refractory EBV reactivation, EBV-related lymphoma, or post-transplant lymphoproliferative disorder (PTLD) following hematopoietic stem cell or solid organ transplantation. It is currently being evaluated in a Phase I/II clinical trial (NCT02580539).
- Other names
- EBV-CTLsEpstein-Barr virus-specific cytotoxic T lymphocytesPeptide-stimulated T cells
02
Targets
EBNA1 (Epstein-Barr virus latency proteins)
Beyond the preview
Go deeper on EBV-specific T-cell lines (Delisle).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBV-specific T-cell lines (Delisle).